Short‐term risks and benefits of hydroxyurea (hydroxycarbamide)‐induced transfusion independence in patients with beta‐thalassaemia syndromes

Key Points

• Hydroxyurea treatment improved transfusion independence in patients with beta-thalassaemia syndromes, showing positive clinical outcomes.
• Patients experienced a reduction in transfusion frequency, with some achieving complete transfusion independence during the treatment.
• The analysis focused on short-term risks associated with hydroxyurea, emphasizing both its advantages and potential adverse effects.
• The findings suggest that hydroxyurea has significant clinical relevance for managing beta-thalassaemia syndromes effectively.